Cytiva Expands Fast Trak Facility in Bengaluru

26 Feb 2026 CW Team

The facility is designed to support multiple modalities including monoclonal antibodies (mAbs), pDNA/mRNA, recombinant proteins and viral vectors. It aims to help biopharma companies across India and Asia-Pacific shorten development timelines, reduce manufacturing risk and scale operations with greater confidence, aligning with India’s ambition to grow its bioeconomy to USD 300 billion by 2030.

Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva, said India’s scientific capabilities play a crucial role in global biopharma, and the expanded infrastructure will enable customers to move from concept to commercialisation with enhanced speed and reliability.

Manoj Panicker, General Manager, Cytiva South Asia, noted that the facility will allow customers to innovate faster while maintaining strong process control, particularly in areas such as rare diseases, emerging modalities and the expanding biosimilars segment.

According to Cytiva’s 2025 Biopharma Index, 56 per cent of global biopharma executives expect domestic biologics manufacturing to rise significantly over the next three years. This trend is particularly visible in India, where demand for biologics and biosimilars continues to grow.

The centre operates in a GLP-compliant biosafety level 2 (BSL-2) environment and supports single-use bioreactor scale-up to 200 L. It can produce toxicity batch material for preclinical studies, while its ISO-certified validation laboratory offers specialised testing and documentation services for sterilising grade filters and single-use systems.

By integrating sustainability best practices with comprehensive technical support, Cytiva aims to enhance yield, improve product quality, reduce manufacturing time and cost, and ensure regulatory compliance—enabling faster progress from early-stage development to commercialisation in an evolving biopharma ecosystem.

Cytiva, a Danaher company, has expanded its Fast Trak process development (PD) and validation services facility in Bengaluru, strengthening India’s position in the global biopharma landscape. The newly inaugurated ~30,000 sq ft centre brings upstream and downstream process development, optimisation, scale-up and validation services under one roof. The facility is designed to support multiple modalities including monoclonal antibodies (mAbs), pDNA/mRNA, recombinant proteins and viral vectors. It aims to help biopharma companies across India and Asia-Pacific shorten development timelines, reduce manufacturing risk and scale operations with greater confidence, aligning with India’s ambition to grow its bioeconomy to USD 300 billion by 2030. Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva, said India’s scientific capabilities play a crucial role in global biopharma, and the expanded infrastructure will enable customers to move from concept to commercialisation with enhanced speed and reliability. Manoj Panicker, General Manager, Cytiva South Asia, noted that the facility will allow customers to innovate faster while maintaining strong process control, particularly in areas such as rare diseases, emerging modalities and the expanding biosimilars segment. According to Cytiva’s 2025 Biopharma Index, 56 per cent of global biopharma executives expect domestic biologics manufacturing to rise significantly over the next three years. This trend is particularly visible in India, where demand for biologics and biosimilars continues to grow. The centre operates in a GLP-compliant biosafety level 2 (BSL-2) environment and supports single-use bioreactor scale-up to 200 L. It can produce toxicity batch material for preclinical studies, while its ISO-certified validation laboratory offers specialised testing and documentation services for sterilising grade filters and single-use systems. By integrating sustainability best practices with comprehensive technical support, Cytiva aims to enhance yield, improve product quality, reduce manufacturing time and cost, and ensure regulatory compliance—enabling faster progress from early-stage development to commercialisation in an evolving biopharma ecosystem.

Infrastructure Urban

10 Mar 2026

ABB to Invest Rs 6.25 Billion to Expand India Manufacturing

ABB recently announced plans to invest approximately Rs 6.25 billion ($75 million) in India during 2026 to expand its manufacturing footprint and research and development capabilities. The investment follows more than $35 million spent in 2025 and reflects the company’s continued focus on strengthening its ‘local-for-local’ strategy in the country.The investment will support ABB’s Electrification, Motion and Automation businesses and expand manufacturing capacity for infrastructure sectors such as renewable energy, metro rail, data centres and industrial applications. Approximately 300..

Equipment

10 Mar 2026

Six WOLFF Cranes Handle 60,000 m³ Concrete for German Hospital

Six WOLFF tower cranes are playing a key role in constructing a new hospital complex in Memmingen, Germany, supporting large-scale material handling for the project. The facility is being built on a 7.7-hectare site and will feature six floors, around 480 beds and a gross floor area exceeding 75,000 sq m.Building shell works began recently in February 2025. One WOLFF 6531.12 Cross crane supported early site preparation before being dismantled in autumn 2025, while five remaining cranes continue operations. Over an average deployment period of 16 months, the cranes are expected to move approxim..

Equipment

10 Mar 2026

REC Funds Rs 115.6 Million CSR Support for Bihar Eye Hospital

REC recently committed Rs 115.6 million under its Corporate Social Responsibility (CSR) programme for the procurement of clinical and non-clinical equipment at Sankara Eye Hospital in Saharsa, Bihar. The initiative aims to strengthen healthcare infrastructure and improve access to specialised eye care services in the region.A Memorandum of Agreement (MoA) was recently signed between Pradeep Fellows, Executive Director (CSR), REC Limited, and Wg Cdr V. Shankar (Retd), Trustee and Executive Director of Sankara Eye Hospital, at the REC office in the SCOPE Complex, New Delhi.The support is expecte..